Companion Diagnostic Co-Development
We Build. We Validate. We Deliver.
ResearchDx integrates and aligns IVD and pharma development that simplifies, speeds and ensures delivery of your FDA-approved companion diagnostics.
Blood-Based Biomarkers Discriminate IBS from IBD with High Degree of Certainty in Patients with Chronic Diarrhea
Brief: Two blood-based biomarkers, cytolethal distending toxin B (CdtB) and anti-vinculin, have been substantively linked with the occurrence of diarrhea-predominant forms of irritable bowel syndrome (IBS). As a result, an ELISA-based diagnostic test developed by Gemelli Biotech is now able to “rule-in” an IBS diagnosis while “ruling-out” irritable bowel disease (IBD) based on elevated biomarker […]
Read More